GlassScriptPhysician profile
Maygoe R Sheehan
NPI 1073772729
$2,796.69
in general payments reported to CMS, 2019-2025
29 companies · $43.07 in 2025
The $43.07 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $740 · 2020: $332 · 2021: $13.72 · 2022: $499 · 2023: $608 · 2024: $561 · 2025: $43.07.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,212.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,211.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $780.97 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Sanofi-Aventis U.S. LLC | $241.64 | 2019-2024 | |
| Gilead Sciences, INC. | $234.15 | 2019-2024 | |
| Novo Nordisk INC | $206.65 | 2019-2025 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $194.84 | 2019-2024 | Gardasil 9, Vaxneuvance, Pneumovax 23 |
| Pfizer INC. | $171.31 | 2019-2024 | |
| Abbvie INC. | $114.70 | 2023-2024 | Vraylar |
| Astrazeneca Pharmaceuticals LP | $111.53 | 2020-2024 | Farxiga, Airsupra |
| Teva Pharmaceuticals USA, INC. | $88.81 | 2020-2023 | Austedo |
| Viiv Healthcare Company | $78.62 | 2019-2021 | |
| Shield Therapeutics INC | $78.38 | 2023-2024 | Accrufer |
| Lilly USA, LLC | $53.87 | 2022-2024 | Jardiance, Mounjaro, Zepbound |
| Allergan, INC. | $41.39 | 2020 | |
| Novartis Pharmaceuticals Corporation | $40.05 | 2019-2024 | |
| Sanofi Pasteur INC. | $39.19 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.45 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $38.21 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $36.99 | 2024 | Spravato |
| Amarin Pharma, INC. | $32.43 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $23.71 | 2023 | Keveyis |
| Vifor Pharma, INC. | $20.62 | 2019 | |
| Mannkind Corporation | $18.69 | 2019 | |
| Phathom Pharmaceuticals, INC. | $18.44 | 2023 | Voquezna |
| Seqirus USA INC | $17.26 | 2024 | Flucelvax, Fluad |
| Janssen Biotech, INC. | $16.96 | 2022 | |
| Amgen INC. | $15.82 | 2023 | Otezla, Repatha |
| Exact Sciences Corporation | $14.46 | 2024 | Cologuard Collection Kit |
| Smith+Nephew, INC. | $14.37 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.18 | 2024 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maygoe Sheehan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.